The maker of a drug shown to shorten recovery time for severely ill COVID-19 patients says it will charge $2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries. More
There’s another coronavirus. This one, causing horrific swelling in cats, even killing them. Gilead Pharmacueticals might have a drug that can cure this feline coronavirus. Yet, they’re not sharing that drug, possibly because they’re scared it might harm their chances with another drug: Remdesivir. You may have heard of it; it’s the supposed ‘gold standard’ of care for COVID-19. The story of Remdesivir (and of the black market cat drug sibling) reveals how pharmaceutical companies do their research, and the lengths they go to protect their profits. More
The case is the latest inquiry into pharmaceutical companies’ donations to patient assistance charities, which have been blamed for inflating the cost of drugs. More
Inmates at Angola prison in Louisiana told ProPublica of widespread illness, dysfunctional care and deadly neglect as the coronavirus outbreak hit. More
How much should remdesivir cost? This question puts two drug-value organizations at odds. More
The state's largest health care network says cost-saving measures will affect 50,000 workers across the company. More
U.S. health care prices are unregulated, opaque and unpredictable. When Congress required insurers to cover Covid-19 testing, a few providers decided to take advantage. More
During the pandemic, unions representing front-line medical staffers have stepped forward to advocate aggressively on behalf of their members. In some cases, they've won paid sick leave and hazard pay—and nonunion workers are watching. More
Visits from pharmaceutical sales reps haven't stopped during the pandemic--they've just moved online... More
Patients who were treated for the virus are largely supposed to be exempt from receiving large bills. One hospital erroneously sent one. More
The outbreak at a California prison — described by inmates to STAT — show how a piecemeal response and prison conditions have fueled the virus' spread. More
The COVID-19 patient, from West Seattle, has insurance and so isn't on the hook for the vast majority of the charge. But the gold-plated cost highlights one reason why American health care is so hard to reform. More
TeamHealth, a medical staffing firm owned by private-equity giant Blackstone, charges multiples more than the cost of ER care. All the money left over after covering costs goes to the company, not the doctors who treated the patients. More
The critical questions the Stanford professor is raising about Covid-19 have gotten lost amid partisan bickering, write Shannon Brownlee and Jeanne Lenzer.
More
America has failed the Covid-19 test, and it’s the accumulated result of policy and market decisions. More
Twenty-six drug manufacturers were sued on Wednesday by the attorneys general of most U.S. states and several territories, which accused them of conspiring to reduce competition and drive up generic drug prices. More
Dozens of top recipients of government aid have laid off, furloughed or cut the pay of tens of thousands of employees. More
Recent analyses by multiple think tanks indicate that tens of millions of Americans could lose their employer-sponsored health coverage. More
Deploying these corrosive, inhalable chemicals could harm people in several ways: exposing more people to the virus, compromising the body’s ability to fight off the infection and even causing mild infections to become more severe illnesses. More
Rural Oklahoma communities are desperate to protect their vulnerable hospitals and hand the reins to management companies that say they’re turnaround experts. Instead some companies failed the hospitals, bled them dry and expedited their demise. More